By Kurt Orzeck ( April 26, 2016, 11:13 PM EDT) -- The U.S. Federal Trade Commission said Tuesday it had unanimously approved a settlement under which Lupin Ltd. will divest two generic drugs sold by Gavis Pharmaceuticals LLC, after the FTC claimed Lupin's $850 million acquisition of Gavis would likely be anti-competitive....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.